260 related articles for article (PubMed ID: 33256675)
1. Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication.
Waters T; Goss KL; Koppenhafer SL; Terry WW; Gordon DJ
BMC Cancer; 2020 Nov; 20(1):1171. PubMed ID: 33256675
[TBL] [Abstract][Full Text] [Related]
2. The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation.
Vogel JU; Schmidt S; Schmidt D; Rothweiler F; Koch B; Baer P; Rabenau H; Michel D; Stamminger T; Michaelis M; Cinatl J
Cells; 2019 Dec; 9(1):. PubMed ID: 31861948
[TBL] [Abstract][Full Text] [Related]
3. Effects of Iron Chelation in Osteosarcoma.
Argenziano M; Di Paola A; Tortora C; Di Pinto D; Pota E; Di Martino M; Perrotta S; Rossi F; Punzo F
Curr Cancer Drug Targets; 2021; 21(5):443-455. PubMed ID: 33380300
[TBL] [Abstract][Full Text] [Related]
4. Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis.
Punzo F; Tortora C; Argenziano M; Casale M; Perrotta S; Rossi F
PLoS One; 2018; 13(12):e0208102. PubMed ID: 30507954
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag inhibits Type I interferon-mediated antiviral signaling by decreasing cellular iron.
Ma S; Liu A; Hu X; Feng Q; Zhang Y; Li N; Peng J; Sheng Z
Biochem Pharmacol; 2021 Apr; 186():114436. PubMed ID: 33539815
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia.
Qanash H; Li Y; Smith RH; Linask K; Young-Baird S; Hakami W; Keyvanfar K; Choy JS; Zou J; Larochelle A
Cells; 2021 Mar; 10(4):. PubMed ID: 33810313
[TBL] [Abstract][Full Text] [Related]
7. Initial
Nevil G; Roth M; Gill J; Zhang W; Teicher B; Erickson SW; Gatto G; Smith M; Kolb EA; Gorlick R
Pediatr Hematol Oncol; 2021 Feb; 38(1):8-13. PubMed ID: 32804009
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Kühne T; Imbach P
Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
[TBL] [Abstract][Full Text] [Related]
9. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
Will B; Kawahara M; Luciano JP; Bruns I; Parekh S; Erickson-Miller CL; Aivado MA; Verma A; Steidl U
Blood; 2009 Oct; 114(18):3899-908. PubMed ID: 19710504
[TBL] [Abstract][Full Text] [Related]
10. Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress.
Croushore EE; Koppenhafer SL; Goss KL; Geary EL; Gordon DJ
Cancer Res Commun; 2023 Aug; 3(8):1580-1593. PubMed ID: 37599787
[TBL] [Abstract][Full Text] [Related]
11. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
12. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag for treatment of thrombocytopenia-associated disorders.
Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia.
Guan Y; Hasipek M; Jiang D; Tiwari AD; Grabowski DR; Pagliuca S; Kongkiatkamon S; Patel B; Singh S; Parker Y; LaFramboise T; Lindner D; Sekeres MA; Mian OY; Saunthararajah Y; Maciejewski JP; Jha BK
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35085104
[TBL] [Abstract][Full Text] [Related]
15. Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review.
Wang XL; Li AM
Blood Coagul Fibrinolysis; 2016 Oct; 27(7):825-827. PubMed ID: 26650460
[TBL] [Abstract][Full Text] [Related]
16. Eltrombopag to allow chemotherapy in a patient with MYH9-related inherited thrombocytopenia and pancreatic cancer.
Paciullo F; Bury L; Gresele P
Int J Hematol; 2020 Nov; 112(5):725-727. PubMed ID: 32557126
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.
Kao YR; Chen J; Narayanagari SR; Todorova TI; Aivalioti MM; Ferreira M; Ramos PM; Pallaud C; Mantzaris I; Shastri A; Bussel JB; Verma A; Steidl U; Will B
Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209246
[TBL] [Abstract][Full Text] [Related]
18. Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia.
Lambert MP; Witmer CM; Kwiatkowski JL
Am J Hematol; 2017 Jun; 92(6):E88-E91. PubMed ID: 28240793
[No Abstract] [Full Text] [Related]
19. The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.
Jeong JY; Levine MS; Abayasekara N; Berliner N; Laubach J; Vanasse GJ
J Hematol Oncol; 2015 Apr; 8():37. PubMed ID: 25886818
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations.
Serebruany VL; Eisert C; Sabaeva E; Makarov L
Am J Ther; 2010; 17(1):68-74. PubMed ID: 19451811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
